检索结果 - David R. Spigel

Refine Results
  1. 1
    Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

    Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance 由 Robert M. Jotte, David R. Spigel

    出版 2015
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches

    Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches 由 David R. Spigel, Mark A. Socinski

    出版 2013
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer

    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer 由 Leora Horn, Martin Reck, David R. Spigel

    出版 2016
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study

    Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study 由 John D. Hainsworth, David R. Spigel, Sharlene Litchy, F. Anthony Greco

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology

    Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology 由 F. Anthony Greco, Wayne J. Lennington, David R. Spigel, John D. Hainsworth

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network

    Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network 由 John D. Hainsworth, David R. Spigel, C. Farley, Dana S. Thompson, Dianna Shipley, F. Anthony Greco

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

    Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib 由 John D. Hainsworth, Jeffrey A. Sosman, David R. Spigel, Donna L. Edwards, Cara Baughman, Anthony Greco

    出版 2005
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts 由 Martin Reck, Fabrice Barlési, Lucio Crinò, Claudia I. Henschke, Dolores Isla, Susanne Stiebeler, David R. Spigel

    出版 2011
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  9. 9
    Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction

    Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction 由 F. Anthony Greco, David R. Spigel, Denise A. Yardley, Mark G. Erlander, Xiaojun Ma, John D. Hainsworth

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

    Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the... 由 John D. Hainsworth, Mark S. Rubin, David R. Spigel, Ralph V. Boccia, Samuel Raby, Raven Quinn, F. Anthony Greco

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History

    High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History 由 Bert H. O’Neil, Robert M. Allen, David R. Spigel, Thomas E. Stinchcombe, Dominic T. Moore, Jordan Berlin, Richard M. Goldberg

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

    Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site 由 John D. Hainsworth, David R. Spigel, Dana S. Thompson, Patrick Murphy, Cassie M. Lane, David Waterhouse, Yuval Naot, F. Anthony Greco

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer

    Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer 由 John D. Hainsworth, David R. Spigel, C. Farley, Dianna Shipley, James D. Bearden, Jitendra G. Gandhi, Gerry Ann Houston, F. Anthony Greco

    出版 2007
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

    PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 由 Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

    P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 由 Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer

    Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer 由 David R. Spigel, F. Anthony Greco, John D. Zubkus, Patrick Murphy, Ruben A. Saez, C. Farley, Denise A. Yardley, Howard A. Burris, John D. Hainsworth

    出版 2009
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

    Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial 由 David R. Spigel, P. Townley, David Waterhouse, Fang Ting Liang, İbrahim Adıgüzel, Jane E. Huang, David A. Karlin, Leonardo Faoro, Frank A. Scappaticci, Mark A. Socinski

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung 由 David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort

    Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor... 由 Howard A. Burris, Suzanne J. Bakewell, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, David R. Spigel, Glen J. Weiss, Ramesh K. Ramanathan, Angela Ogden, Daniel D. Von Hoff

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study 由 John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Herbert I. Hurwitz, David R. Spigel, Christopher J. Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: